Chromogranins can be measured in samples from cats and dogs

BMC Research Notes

Odd Höglund¹  Christoffer Westin¹  Ragnvi Hagman¹  Ann Pettersson¹  Mats Stridsberg² 

[1] Department of Clinical Sciences, Swedish University of Agricultural Sciences, Box 7054, SE-750 07 Uppsala, Sweden;Department of Medical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden

关键词: Radioimmunoassay;    Human;    Feline;    Canine;    Secretogranin;    Chromogranin;   

Others  :  1132587
DOI  :  10.1186/1756-0500-7-336

 received in 2013-10-15, accepted in 2014-05-28,  发布年份 2014

【 摘 要 】

Background

Methods for objective evaluation of stress in animals are important, but clinically difficult. An alternative method to study the sympathetic activity may be to investigate Chromogranin A (CGA), Chromogranin B (CGB) and Secretogranin II (SG2). The aim of this study was to investigate the cross-reactivity of CGA, CGB and SG2 between man, cat and dog and to explore possibilities to measure these proteins in samples from cats and dogs.

Results

Adrenal gland extracts from feline and canine species were measured by region-specific radioimmunoassays in different dilution steps to explore possible inter species cross reactivity. High cross reactivity was found for cats in the CGA17-38, CGA324-337, CGA361-372, CGB and SG2 assays. High cross reactivity was found for dogs in the CGA17-38, CGA361-372, CGB and SN assays. The method measuring the intact CGA was not useful for measurements in cats and dogs.

Conclusions

Region-specific assays measuring defined parts of CGA, CGB and SG2 can be used for measurements in samples from cats and dogs. These results are promising and will allow for further studies of these proteins as possible clinical biomarkers in cats and dogs.

【 授权许可】

   
2014 Stridsberg et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Taupenot L, Harper KL, O’Connor DT: The chromogranin-secretogranin family. N Engl J Med 2003, 348:1134-1149.
• [2]Cryer PE, Wortsman J, Shah SD, Nowak RM, Deftos LJ: Plasma chromogranin A as a marker of sympathochromaffin activity in humans. Am J Physiol 1991, 260:E243-E246.
• [3]d’Herbomez M, Do Cao C, Vezzosi D, Borzon-Chasot F, Baudin E: Chromogranin A assay in clinical practice. Ann Endocrinol (Paris) 2010, 71:274-280.
• [4]Zhang D, Lavaux T, Sapin R, Lavigne T, Castelain V, Aunis D, Metz-Boutigue MH, Schneider F: Serum concentration of chromogranin A at admission: an early biomarker of severity in critically ill patients. Ann Med 2009, 41:38-44.
• [5]Zhang D, Lavaux T, Voegeli AC, Lavigne T, Castelain V, Meyer N, Sapin R, Aunis D, Metz-Boutigue MH, Schneider F: Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin Chem 2008, 54:1497-1503.
• [6]Røsjø H, Nygård S, Kaukonen KM, Karlsson S, Stridsberg M, Ruokonen E, Pettilä V, Omland T: Prognostic value of chromogranin A in severe sepsis: data from the FINNSEPSIS study. Intensive Care Med 2012, 38:820-829.
• [7]Røsjø H, Opstad PK, Hoff JE, Godang K, Christensen G, Stridsberg M, Omland T: Effect of short- and long-term physical activities on circulating granin protein levels. Regul Pept 2013, 185C:14-19.
• [8]Lindahl AE, Low A, Stridsberg M, Sjoberg F, Ekselius L, Gerdin B: Plasma chromogranin A after severe burn trauma. Neuropeptides 2013, 47:207-212.
• [9]Stridsberg M, Angeletti RH, Helle KB: Characterisation of N-terminal chromogranin A and chromogranin B in mammals by region-specific radioimmunoassays and chromatographic separation methods. J Endocrinol 2000, 165:703-714.
• [10]Stridsberg M, Eriksson B, Öberg K, Janson ET: A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A. Regul Pept 2004, 117:219-227.
• [11]Stridsberg M, Eriksson B, Janson ET: Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. Regul Pept 2008, 148:95-98.
• [12]Hagn C, Schmid KW, Fischer-Colbrie R, Winkler H: Chromogranin A, B, and C in human adrenal medulla and endocrine tissues. Lab Invest 1986, 55:405-411.
• [13]Helle KB: Chromogranins A and B and secretogranin II as prohormones for regulatory peptides from the diffuse neuroendocrine system. Results Probl Cell Differ 2010, 50:21-44.
• [14]Goetze JP, Alehagen U, Flyvbjerg A, Rehfeld JF: Making sense of chromogranin A in heart disease. Lancet Diabetes Endocrinol 2013, 1:7-8.
• [15]Takiyyuddin MA, Neumann HP, Cervenka JH, Kennedy B, Dinh TQ, Ziegler MG, Baron AD, O’Connor DT: Ultradian variations of chromogranin A in humans. Am J Physiol 1991, 261:R939-R944.
• [16]Myers NC 3rd, Andrews GA, Chard-Bergstrom C: Chromogranin A plasma concentration and expression in pancreatic islet cell tumors of dogs and cats. Am J Vet Res 1997, 58:615-620.
• [17]Akiyoshi H, Aoki M, Shimada T, Noda K, Kumagai D, Saleh N, Sugii S, Ohashi F: Measurement of plasma chromogranin A concentrations for assessment of stress responses in dogs with insulin-induced hypoglycemia. Am J Vet Res 2005, 66:1830-1835.
• [18]Akiyoshi H, Sugii S, Nahid MA, Sone K, Tanaka T, Zheng C, Yijyun L, Aoki M, Takenaka S, Shimada T, Shimizu J, Kiyomiya K, Ohashi F: Detection of chromogranin A in the adrenal gland extracts of different animal species by an enzyme-linked immunosorbent assay using Thomsen-Friedenreich antigen-specific Amaranthus caudatus lectin. Vet Immunol Immunopathol 2011, 144:255-258.
• [19]Kanai K, Hino M, Hori Y, Nakao R, Hoshi F, Itoh N, Higuchi S: Circadian variations in salivary chromogranin a concentrations during a 24-hour period in dogs. J Vet Sci 2008, 9:421-423.